Long-acting injectable formulation technologies: Challenges and opportunities for the delivery of fragile molecules July 28, 2022 July 28, 2022
MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000 July 27, 2022 July 27, 2022
MedinCell announces its full year financial results April 2021 – March 2022 June 14, 2022 June 14, 2022
Videoconference and release of fiscal 2021-2022 financial results on June 14, 2022 June 7, 2022 June 7, 2022
MedinCell: US Pharma Development expert Richard Malamut, MD becomes Chief Medical Officer May 9, 2022 May 9, 2022
MedinCell’s partner Teva provides additional information regarding the New Drug Application for mdc-IRM May 3, 2022 May 3, 2022
MedinCell provides additional information regarding the new drug application for mdc-IRM April 19, 2022 April 19, 2022
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM April 19, 2022 April 19, 2022
MedinCell: inclusion of first participants in new Covid-19 prophylaxis clinical trial SAIVE March 28, 2022 March 28, 2022
Intra-articular delivery of full-length antibodies through the use of an in situ forming depot December 12, 2021 December 12, 2021
